| Allopurinol does not decrease blood pressure or prevent the development of hypertension in the deoxycorticosterone acetate-salt rat model. | |
| | |
MedLine Citation:
|
PMID: 20881613 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Reactive oxygen species play an important role in the pathogenesis of hypertension, disease in which reactive oxygen species levels and markers of oxidative stress are increased. Xanthine oxidase (XO) is a reactive oxygen species-producing enzyme the activity of which may increase during hypertension. Studies on XO inhibition effects on blood pressure have yielded controversial results. We hypothesized that XO inhibition would decrease blood pressure or attenuate the development of deoxycorticosterone acetate (DOCA)-salt hypertension. We administered the XO inhibitor, allopurinol (50 mg/kg per day, orally) or its vehicle to rats during the established or development stages of DOCA-salt hypertension. We validated XO inhibition by high-performance liquid chromatography measurements of XO metabolites in urine, serum, and tissues demonstrating a decrease in products, increase in substrates, and detection of the active metabolite of allopurinol, oxypurinol. We monitored blood pressure continuously through radiotelemetry and performed gross evaluations of target organs of hypertension. Allopurinol treatment did not impact the course of DOCA-salt hypertension regardless of the timing of administration. Aside from a significant decrease in pulse pressure in allopurinol-treated rats, no positive differences were observed between the allopurinol and the vehicle-treated rats. We conclude that XO does not play an important role in the development or maintenance of hypertension in the rat DOCA-salt hypertension model. |
| | |
Authors:
|
Theodora Szasz; A Elizabeth Linder; Robert P Davis; Robert Burnett; Gregory D Fink; Stephanie W Watts |
Related Documents
:
|
7697963 - Counter irritation test in primary fibromyalgia. 3481633 - Calcium antagonism and protection of tissues from calcium damage. 18556383 - Volume overhydration is related to endothelial dysfunction in continuous ambulatory per... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 56 ISSN: 1533-4023 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2011-04-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 627-34 Citation Subset: IM |
Affiliation:
|
Pharmacology and Toxicology Department, Michigan State University, East Lansing, MI 48824-1317, USA. szasziri@msu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
P01 HL70687/HL/NHLBI NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiangiogenic and antimitotic effects of aspirin in hypoxia–reoxygenation modulation of the LOX-1...
Next Document: Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricul...